Maturitas
Volume 60, Issue 1 , Pages 3-9 , 20 May 2008

What is the optimal policy for osteoporosis management?

Received 6 November 2007 ,Revised 13 February 2008 ,Accepted 20 February 2008.

References 

  1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization Technical Report Series 1994; 843:1–129.
  2. Report of the Advisory Group on Osteoporosis. Department of Health, London; 1994.
  3. Royal College of Physicians . Osteoporosis: clinical guidelines for prevention and treatment. London: Royal College of Physicians; 1999;
  4. Cranney A, Guyatt G, Griffith L, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summaries of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570–578
  5. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9:1–160
  6. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen and progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial. JAMA. 2003;290:1729–1738
  7. EMEA public statement on recent publications regarding hormone replacement therapy. European Agency for the Evaluation of Medicinal Products, post-authorisation evaluation of medicines for human use, EMEA/33065/03. London; December 3, 2003.
  8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–333
  9. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419–427
  10. Further advice on safety of HRT: Risk: benefit unfavourable for first-line use in prevention of osteoporosis. CEM/CMO/2003/19, Committee of Safety of Medicines; December 3, 2003.
  11. Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. A position paper of the IOF and NOF. Osteoporosis Int. 2002;13:527–536
  12. NICE website: www.nice.org.uk.
  13. Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res. 1992;7:1467–1474
  14. Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas. 2006;54:176–180
  15. Bagger YZ, Tanko LB, Alexandersen F, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone. 2004;34:728–735
  16. Siris ES, Brenneman SK, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporosis Int. 2006;17:565–574
  17. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–1936

PII: S0378-5122(08)00074-1

doi: 10.1016/j.maturitas.2008.02.012

Maturitas
Volume 60, Issue 1 , Pages 3-9 , 20 May 2008

Article Tools